Lara Sullivan, M.D.
CIK 1769457 · View on SEC EDGAR ↗
First SEC filing: Oct. 7, 2021 · Latest: April 2, 2025
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Sept. 18, 2023 | PYXS | S | 8,541 | $2.10 | $17,936 | 2,403,882 Direct | -0.35% | Disposed | 53.8% (price as of 2026-08-20) |
| Sept. 14, 2023 | PYXS | S | 100 | $2.25 | $225 | 2,412,423 Direct | 0.00% | Disposed | 43.6% (price as of 2026-08-20) |
| Sept. 13, 2023 | PYXS | S | 3,000 | $2.27 | $6,810 | 2,597,265 Direct | -0.12% | Disposed | 42.3% (price as of 2026-08-20) |
| Sept. 12, 2023 | PYXS | S | 4,917 | $2.25 | $11,063 | 2,600,265 Direct | -0.19% | Disposed | 43.6% (price as of 2026-08-20) |
| Sept. 11, 2023 | PYXS | S | 20,000 | $2.27 | $45,400 | 2,605,182 Direct | -0.76% | Disposed | 42.3% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 31, 2025 | PYXS | Stock Option (Right to Buy) | Common Stock (918,308) | $0.98 | March 31, 2035 | 918,308 | Acquired |
| Dec. 23, 2024 | PYXS | Stock Option (Right to Buy) | Common Stock (1,135,000) | $1.67 | Dec. 23, 2034 | 1,135,000 | Acquired |
| March 26, 2024 | PYXS | Stock Option (Right to Buy) | Common Stock (1,071,242) | $3.83 | March 26, 2034 | 1,071,242 | Acquired |
| March 24, 2023 | PYXS | Stock Option (Right to buy) | Common Stock (61,825) | — | Sept. 14, 2031 | 61,825 | Acquired |
| March 24, 2023 | PYXS | Stock Option (Right to buy) | Common Stock (990,461) | — | March 30, 2031 | 990,461 | Acquired |
| March 24, 2023 | PYXS | Stock Option (Right to buy) | Common Stock (61,825) | — | Sept. 14, 2031 | 61,825 | Disposed |
| March 24, 2023 | PYXS | Stock Option (Right to buy) | Common Stock (990,461) | — | March 30, 2031 | 990,461 | Disposed |
| Oct. 7, 2021 | PYXS | Stock Option (Right to buy) | Common Stock (962,289) | $16.00 | Oct. 7, 2031 | 962,289 | Acquired |
| June 6, 2019 | IRD | Stock Option (right to buy) | Common Stock (3,537) | $5.23 | June 6, 2029 | 3,537 | Acquired |
| Feb. 27, 2019 | IRD | Stock Option (right to buy) | Common Stock (84,968) | $0.53 | Feb. 27, 2019 | 84,968 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $646,875 | — | — | $723,076 | $291,094 | — | $10,500 | $1,671,545 |
| 2024 | $625,000 | — | $1,249,152 | $4,766,566 | $421,875 | — | $10,350 | $7,072,943 |
| 2023 | $625,000 | $200,000 | $2,686,510 | $546,091 | $375,000 | — | $9,900 | $4,442,501 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.